VMware by IKOULA: An Introductory Offer to Familiarize Yourself With The VMware Environment, While Controlling Your Budget
25.5.2021 11:00:00 EEST | Business Wire | Press release
Nowadays virtualization and hyperconvergence are among the concerns of many companies, IKOULA – a key player in the European IaaS market – aims to democratize the use of VMware technology by offering a VMware introductory offer, packaged to create and operate its own virtual datacenter(s), with a low budget.
Available at €69 / month excl. VAT, this introductory offer includes 1 vCPU (2,9 Ghz), 4 GB of vRAM, 100 GB of hard disk, 1 IPv4 address and an unlimited traffic volume.
Bringing together in a single secure environment all the storage, computing and network resources necessary for any activities, the VMware Cloud Director solution puts an end to physical infrastructures in silos, and guarantees companies an optimized use of these material resources, with a maximized ROI, controlled costs as well as the interoperability and portability of their applications between their different clouds.
What are the benefits for companies using VMware?
- Simplified provisioning and consumption: users benefit from a single access point, making it very easy to provision all kinds of cloud services, but also third-party services, such as Kubernetes containers or programming interfaces for DevOps.
- Flexibility and responsiveness: companies will be able at any time and with just a few clicks to deploy usual or highly personalized services according to their needs.
- Simple migration of workloads between different virtual data centers.
- Optimized IT costs, thanks to the consolidation of resources managed through a single interface and the automation of some IT tasks.
- 100% French hosting of all data, in accordance with the GDPR, avoiding any foreign interference.
- Technical support available 24/7
About IKOULA
Pioneer of the French Cloud since 1998, IKOULA has its own Datacenters in France, as well as two subsidiaries, in Spain and in the Netherlands. Because people are part of its DNA, IKOULA maintains a close relationship with its customers, and provides them with teams of experts available 24/7, to advise and support them in their activities. IKOULA's teams are also multilingual, in order to respond to the internationalization issues of all of its customers, located in more than 60 countries on 4 continents.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005042/en/
Contact information
Press contacts
Laurane VASSOR ARCARO – communication director
lvassorarcaro@ikoula.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla to Meet With Mobile Game Developers and Publishers at Pocket Gamer Connects Barcelona 202611.6.2026 16:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced its participation in Pocket Gamer Connects (PGC) Barcelona 2026, taking place June 15-16 at the Hyatt Regency Barcelona in Barcelona, Spain. Xsolla will be on the ground for meetings with mobile game developers, publishers, and strategic partners, bringing its direct-to-consumer commerce infrastructure to one of the most deal-focused events in the European games calendar. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611487209/en/ Graphic: Xsolla Now in its second year, PGC Barcelona has quickly established itself as a destination conference for mobile game businesses, drawing more than 1,000 attendees from over 47 countries and facilitating thousands of structured business meetings through its dedicated matchmaking platform. Barcelona itself has become one of Europe's most significant gaming cities, home to studios including Scopely, King, Rovio, Band
Onera Will Showcase Its Onera hPSG® Solution at the SLEEP 2026 Conference June 14-17, 2026 in Baltimore, MD, USA.11.6.2026 16:00:00 EEST | Press release
Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2026 conference. The medtech company will showcase this innovative solution at booth #600 during the largest annual sleep medicine conference, which brings together leading experts and innovators in the field. Furthermore, in anticipation of new CPT codes, Onera Health will host an educational symposium on Scaling PSG for the Next Decade: Expanding Utilization of High-Complexity Home Testingon Monday, June 15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611302332/en/ Onera hPSG® – Bringing PSG Home. “We are excited to see our Onera hPSG® solution highlighted at this important meeting in three different presentations and an educational seminar. Onera hPSG® is positioned to be an integral par
IQM Quantum Computer Goes Live at Supercomputing Center CINECA in Italy, Boosting National Compute Infrastructure and Research11.6.2026 15:50:00 EEST | Press release
The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe's leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611898215/en/ The moment Italy's second IQM quantum computer went live at CINECA in Bologna. IQM has previously announced its ongoing business combination with Real Asset Acquisition Corp (Nasdaq: RAAQ), which will result in IQM becoming a public company in mid-2026. The installation, located at the CINECA headquarters in the DAMA Tecnopolo in Bologna, represents not just technological progress but a strategic Italian asset providing concrete tools for the scientific community and businesses to foster innovation, accelerate research, and transform knowledge into high-impact applications.
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom